Temozolomide, an oral chemotherapeutic agent with potential severe toxicity;Temozolomide, een oraal chemotherapeuticum met soms ernstige toxiciteit

Nederlands Tijdschrift voor Geneeskunde

Volumn 151, Issue 4, 2007, Pages 253-257

  Soetekouw, P M M B ^a   Gijtenbeek, J M M ^a   Van Der Maazen, R W M ^a   Kappelle, A C ^a   Van Herpen, C M L ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE;

ADULT; ARTICLE; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CASE REPORT; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FEVER; GLIOBLASTOMA; HUMAN; NEUTROPENIA; PRESCRIPTION; SEPSIS; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; FATAL OUTCOME; FEMALE; FEVER; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA;

EID: 33846861052     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Kros JM. Indeling en gradering van gliale tumoren. Ned Tijdschr Geneeskd. 1996;140:292-7.
2. Bent MJ van den, Schellens JH, Sillevis Smitt PA, Vecht CJ. Chemotherapie bij hersentumoren. Ned Tijdschr Geneeskd. 1996;140:702-6.
3. Stupp R, Mason WP, Bent MJ van den, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. N Engl J Med. 2005;352:987-96.
4. Bromberg JE, Postma TJ. Temozolomide bij patiënten met een glioblastoma multiforme: nieuwe ontwikkelingen. Ned Tijdschr Geneeskd. 2005;149:1376-8.
5. Taal W, Rijt CDD van der, Sillevis Smitt PAE, Kros JM, Heuvel I van, Enting RH, et al. Gunstig resultaat van temozolomide bij een recidief van een hooggradig glioom. Ned Tijdschr Geneeskd. 2005;149:1393-9.
6. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999;17:2762-71.
7. Chinot OL, Barrie M, Frauger E, Dufour H, Figarella-Branger D, Palmari J, et al. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer. 2004;100:2208-14.
8. Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol. 2003;21:646-51.
9. Everaert E, Neyns B, Joosens E, Strauven T, Branie F, Menten J. Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium. J Neurooncol. 2004;70:37-48.
10. Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol. 2001;19:2449-55.
11. Villano JL, Collins CA, Manasanch EE, Ramaprasad C, Besien K van. Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. Lancet Oncol. 2006;7:436-8.
12. Schiffer CA, Anderson CK, Bennett CL, Bernstein S, Elting LS, Goldsmith M, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1519-38.
13. Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005;10:427-37.
14. Blay JY, Chauvin F, Le Cesne A, Anglaret B, Bouhour D, Lasset C, et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol. 1996;14:636-43.
15. Ray-Coquard I, Borg C, Bachelot T, Sebban C, Philip I, Clapisson G, et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer. 2003;88:181-6.